| 產(chǎn)品編號 | bs-12367R-FITC |
| 英文名稱 | Rabbit Anti-TAZ/FITC Conjugated antibody |
| 中文名稱 | FITC標(biāo)記的轉(zhuǎn)錄共激活因子TAZ抗體 |
| 別 名 | Transcriptional co activator with PDZ binding motif; Transcriptional coactivator with PDZ binding motif; Transcriptional coactivator with PDZ-binding motif; WW domain containing transcription regulator 1; WW domain containing transcription regulator protein 1; WW domain-containing transcription regulator protein 1; WWTR 1; WWTR1; WWTR1_HUMAN. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 細(xì)胞生物 信號轉(zhuǎn)導(dǎo) 細(xì)胞凋亡 細(xì)胞周期蛋白 轉(zhuǎn)錄調(diào)節(jié)因子 表觀遺傳學(xué) |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, ) |
| 產(chǎn)品應(yīng)用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 44kDa |
| 細(xì)胞定位 | 細(xì)胞膜 |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human TAZ |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: The transcriptional co-activator with PDZ-binding motif (TAZ) is a 14-3-3-binding molecule. The highly conserved and ubiquitously expressed 14-3-3 proteins regulate differentiation, cell cycle progression and apoptosis by binding intracellular phosphoproteins involved in signal transduction. TAZ may link events at the plasma membrane and cytosketeton to nuclear transcription in a manner that can be regulated by 14-3-3. TAZ shares homology with the WW domain of Yes-associated protein (YAP) and functions as a transcriptional co-activator by binding to the PPXY motif present on transcription factors. TAZ recognizes immunoreactive protein bands in lysates from MDCK, NIH-3T3 and 293T cells. In addition, COS7, Hep G2, CHO and HeLa cells express endogenous TAZ. 14-3-3 binding requires TAZ phosphorylation on a single Serine 89 residue, resulting in the inhibition of TAZ transcriptional co-activation through 14-3-3-mediated nuclear export. Function: Transcriptional coactivator which acts as a downstream regulatory target in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein MST1/MST2, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. WWTR1 enhances PAX8 and NKX2-1/TTF1-dependent gene activation. Regulates the nuclear accumulation of SMADS and has a key role in coupling them to the transcriptional machinery such as the mediator complex. Regulates embryonic stem-cell self-renewal, promotes cell proliferation and epithelial-mesenchymal transition. Subcellular Location: Nucleus. Cytoplasm. Concentrates along specific portions of the plasma membrane, and accumulates in punctate nuclear bodies. Tissue Specificity: Highly expressed in kidney, heart, placenta and lung. Expressed in the thyroid tissue. Post-translational modifications: Phosphorylated by LATS2 and STK3/MST2. Phosphorylation by LATS2 results in creation of 14-3-3 binding sites, retention in the cytoplasm, and functional inactivation. Phosphorylation results in the inhibition of transcriptional coactivation through YWHAZ-mediated nuclear export. Similarity: Contains 1 WW domain. Database links: UniProtKB/Swiss-Prot: Q9GZV5.1 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
